Subcellular dynamics and functional activity of the cleaved Na⁺ channel β 1 subunit intracellular domain

Alexander S. Haworth^{1,2}, Samantha L. Hodges³, Lori L. Isom³, Christoph G. Baumann^{1,2} and William J. Brackenbury^{1,2*}

¹Department of Biology, University of York, Heslington, York, YO10 5DD, UK

²York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK

³Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

*Corresponding author:

Dr William J. Brackenbury, York Biomedical Research Institute, Department of Biology, University of York, Wentworth Way, Heslington, York YO10 5DD, UK

Email: william.brackenbury@york.ac.uk

Tel: +44 1904 328284

Fax: +44 1904 328505

Running title: β 1 subunits and secretase regulation

Keywords: voltage-gated sodium channel, β secretase, γ -secretase, proteolysis, membrane trafficking.

Abstract

The voltage-gated Na⁺ channel $\beta 1$ subunit, encoded by *SCN1B*, regulates cell surface expression and gating of α subunits, and participates in cell adhesion. $\beta 1$ is cleaved by α/β and γ -secretases, releasing an extracellular domain and intracellular domain (ICD) respectively. Abnormal *SCN1B* expression/function is linked to pathologies including epilepsy, cardiac arrhythmia, and cancer. In this study, we sought to determine the effect of secretase cleavage on $\beta 1$ function in breast cancer cells. Using a series of GFP-tagged $\beta 1$ constructs, we show that $\beta 1$ -GFP is mainly retained intracellularly, particularly in the endoplasmic reticulum and endolysosomal pathway, and accumulates in the nucleus. Reduction in endosomal $\beta 1$ -GFP levels occurred following γ -secretase inhibition, implicating endosomes, and/or the preceding plasma membrane, as important sites for secretase processing. Using live-cell imaging, we report $\beta 1$ -ICD-GFP accumulation in the nucleus. Furthermore, $\beta 1$ -GFP and $\beta 1$ ICD-GFP both increased Na⁺ current, whereas $\beta 1$ STOP-GFP, which lacks the ICD, did not, thus highlighting that the $\beta 1$ -ICD was necessary and sufficient to increase Na⁺ current measured at the plasma membrane. Importantly, although the endogenous Na⁺ current expressed in MDA-MB-231 cells is TTX-resistant (carried by Na_v1.5), the Na⁺ current increased by $\beta 1$ -GFP or $\beta 1$ ICD-GFP was TTX-sensitive. Taken together, this work suggests that the $\beta 1$ -ICD is a critical regulator of α subunit function. Our data further support the notion that γ -secretase may play a key role in regulating $\beta 1$ function in breast cancer cells. This work thus highlights proteolytic processing of $\beta 1$ by secretase cleavage to be a relevant mechanism in diseases associated with abnormal $\beta 1$ function.

Introduction

Voltage-gated Na⁺ channels (VGSCs) are heteromeric complexes consisting of Na⁺-conducting α subunits (Na_v1.1-1.9, encoded by *SCN1A-9A*) and non-pore-forming β subunits (β 1- β 4, encoded by *SCN1B-4B*) (1). The inward Na⁺ current carried by VGSCs is responsible for membrane depolarisation during action potential initiation (2). With the exception of the β 1 alternative splice variant β 1B, β subunits are single-pass transmembrane proteins with a large, extracellular immunoglobulin (Ig) domain and are thus members of the Ig superfamily of cell adhesion molecules (CAMs) (3). The β subunits regulate α subunit trafficking (4,5), gating and kinetics (6,7), mechanosensitivity (8,9), and glycosylation (10). In addition to regulating α subunit function, β subunits also function as CAMs, regulating cell-cell and cell-matrix adhesion via interaction with an array of other CAMs, neurite outgrowth, neuronal pathfinding, fasciculation, and cell migration (11-17). β 1-mediated cell adhesion interactions also recruit ankyrin to adhesion contacts and promote neurite outgrowth via activation of fyn kinase (13,18-20).

Variants in genes encoding VGSC α and β subunits occur in various excitability-linked disorders, including epilepsy and cardiac arrhythmia (21,22). Variants in *SCN1B*, encoding β 1, are associated with developmental and epileptic encephalopathy (DEE56), early infantile DEE (EI-DEE), generalised epilepsy with febrile seizures plus, atrial fibrillation and Brugada syndrome (23-26). *Scn1b* null mice display EI-DEE and disrupted neuronal pathfinding and fasciculation, as well as altered cardiac excitability (27-29). VGSCs are also aberrantly expressed in cancer cells (30). β 1 is upregulated in breast cancer compared to healthy tissue (31). β 1 overexpression in metastatic MDA-MB-231 breast cancer cells increases Na⁺ current, without altering gating kinetics, induces outgrowth of neurite-like processes *in vitro* and increases tumour growth and metastasis *in vivo* (31,32). Taken together, these

observations highlight that *SCN1B* plays a key role in regulating pathophysiological behaviour of excitable and non-excitable cells.

$\beta 1$ interacts with α subunits via extracellular and intracellular sites (4,33,34). Extracellularly, $\beta 1$ contacts extracellular loops within DI, DIII, DIV of $\text{Na}_v1.4$, as well as within the DIII transmembrane domain (35,36). Although an intracellular α - $\beta 1$ interaction site has yet to be resolved, a soluble polypeptide representing the intracellular C-terminus of $\text{Na}_v1.1$ co-immunoprecipitates with $\beta 1$ (34). Furthermore, deletion of the $\beta 1$ intracellular domain (ICD) attenuates $\beta 1$ - $\text{Na}_v1.2$ interaction (4). The locations of α - $\beta 1$ extracellular/intracellular interaction sites are intriguing because β subunits are substrates for regulated intramembrane proteolysis by sequential activity of α - or β -secretase then γ -secretase, releasing the extracellular Ig domain and then the soluble ICD, respectively (37-39). In addition, palmitoylation of $\beta 1$ is required for its proteolytic processing at the plasma membrane (40). The soluble extracellular $\beta 1$ Ig domain has been shown to promote neurite outgrowth (3,17). The $\beta 1$ -ICD and $\beta 2$ -ICD have been shown to accumulate in the nucleus, regulating transcription (39,41). Thus, proteolytic processing of $\beta 1$ plays a key role in regulating adhesion, neurite outgrowth and gene transcription.

γ -secretase activity promotes cancer progression via activation of Notch signalling, and several γ -secretase inhibitors have been pursued in clinical trials (42). Moreover, aberrant $\beta 1$ ICD-mediated transcriptional changes may promote $\beta 1$ -linked pathologies, including epilepsy, cardiac arrhythmia, and cancer (39). Here, we sought to determine the effect of secretase cleavage on $\beta 1$ function in breast cancer cells. Using a series of GFP-tagged $\beta 1$ constructs stably expressed in MDA-MB-231 cells, we found that full-length $\beta 1$ -GFP is mainly retained intracellularly, particularly in the endoplasmic reticulum and endolysosomal pathway, and accumulates in the nucleus. Pharmacological inhibition of γ -secretase

cleavage decreased $\beta 1$ ICD-GFP levels but had no effect on spatiotemporal cycling dynamics of $\beta 1$ -GFP and did not alter Na^+ current. Using live-cell imaging, we report specific $\beta 1$ ICD-GFP accumulation in the nucleus. Furthermore, $\beta 1$ -GFP or $\beta 1$ ICD-GFP overexpression increased Na^+ current, whereas $\beta 1$ STOP-GFP, which lacks the ICD, did not, thus highlighting a requirement for the ICD to promote VGSCs at the plasma membrane. Importantly, although the endogenous Na^+ current expressed in MDA-MB-231 cells is tetrodotoxin (TTX)-resistant (carried by $\text{Na}_v 1.5$) (43,44), the Na^+ current increased by $\beta 1$ -GFP or $\beta 1$ ICD-GFP was TTX-sensitive. Taken together, this work suggests that the proteolytically cleaved $\beta 1$ -ICD is a critical regulator of α subunit function in breast cancer cells. Therefore, this work further highlights proteolytic processing of $\beta 1$ by secretase cleavage to be a relevant mechanism in diseases associated with abnormal $\beta 1$ function.

Results

Plasma membrane expression and activity of $\beta 1$ -GFP

In this study, we used over-expression of $\beta 1$ -GFP in the MDA-MB-231 cell line as a model system in which to study functional consequences of proteolytic processing of $\beta 1$ by secretase cleavage. MDA-MB-231 cells provide a unique model system to analyse $\beta 1$ function for two reasons. Firstly, there is low endogenous β subunit expression in this cell line, thus enabling introduction of engineered $\beta 1$ constructs (32). Secondly, endogenous expression of functional α subunits in MDA-MB-231 cells negates the requirement for exogenous α subunit expression and ensures a native trafficking pathway is present for α subunits to reach the plasma membrane. Initially, Na^+ currents in MDA-MB-231- $\beta 1$ -GFP cells were compared to control MDA-MB-231-GFP cells using whole cell patch clamp recording. Peak Na^+ current density in MDA-MB-231- $\beta 1$ -GFP cells was 3-fold greater than cells expressing GFP alone, -16.80 ± 2.90 pA/pF vs. -5.16 ± 0.71 pA/pF ($P < 0.01$; $n = 8$; t-test; Figure 1A-C). These data suggest that $\beta 1$ -GFP increases α subunit expression at the

plasma membrane, in agreement with previous observations (32). β 1-GFP over-expression did not affect the voltage at activation, voltage at half-maximal activation, rate of activation, voltage at half-inactivation, rate of inactivation, time to current peak, or membrane capacitance (Figure 1D-G and I-M). However, β 1-GFP over-expression caused a hyperpolarisation of the voltage at Na^+ current peak ($P < 0.05$; $n = 8$; t-test; Figure 1H) and accelerated recovery from inactivation ($P < 0.01$; $n = 8$; t-test; Figure 1N, O).

The observations that β 1-GFP over-expression (i) increases Na^+ current and (ii) promotes transcellular adhesion of MDA-MB-231 cells (32) suggest that it is functionally active at the plasma membrane in this cell line. We therefore examined the subcellular localisation of β 1-GFP, initially focusing on plasma membrane expression. Surprisingly, when live MDA-MB-231- β 1-GFP cells were stained with the lipid dye FM4-64, no overlap in fluorescence was detected at the plasma membrane, whereas robust co-localisation was observed within internal vesicles (Figure 2A). In fact, line profile analysis revealed that peak plasma membrane FM4-64 fluorescence and β 1-GFP fluorescence were offset by ~ 500 nm (Figure 2B), suggesting that β 1-GFP is not highly expressed at the plasma membrane. To ensure that the lack of surface β 1-GFP abundance was not due to FM4-64 quenching GFP fluorescence via FRET, FM4-64 was photobleached and the resulting change in GFP fluorescence monitored. Photobleaching of FM4-64 within internal vesicles caused a modest, but significant, 8.9 ± 0.03 % increase in GFP signal ($P < 0.05$; $n = 4$; t-test; Figure 2C), suggesting that some FRET did occur between GFP and FM4-64. However, when FM4-64 was photobleached at the plasma membrane, no increase in GFP signal was detected (Figure 2C), ruling out GFP quenching by FM4-64 as an explanation for the low abundance of β 1-GFP at the cell surface. In summary, although β 1-GFP promotes Na^+ current, most of this protein appears to be retained intracellularly in MDA-MB-231 cells. This observation agrees with a previous study in Madin-Darby canine kidney cells, which showed that β 1 was retained intracellularly, unlike β 2, which was enriched at the plasma membrane (45).

Subcellular distribution of β 1-GFP

The β 1-ICD and β 2-ICD secretase cleavage products localise to the nucleus of heterologous cells and alter gene transcription (39,41). We therefore next investigated whether any β 1-GFP signal localised to the nucleus in MDA-MB-231 cells. Prior to anti-GFP antibody labelling, cells were permeabilised with either Triton X-100, which permeabilises all cellular membranes, permitting access to nuclear antigens, or digitonin, which does not permeabilise the nuclear membrane, preventing access to nuclear antigens (46). The inner nuclear membrane protein, lamin B2, was labelled strongly in Triton X-100 permeabilised cells, but not digitonin-permeabilised cells, confirming that digitonin restricted antibody access to nuclear antigens (Figure 2D). Labelling with the anti-GFP antibody revealed a small but statistically significant 18 % reduction in nuclear:cytoplasmic fluorescence intensity ratio in digitonin-permeabilised cells compared to Triton X-100 permeabilised cells ($P < 0.001$; $n = 26-28$; t-test; Figure 2E, F), suggesting that a fraction of β 1-GFP is indeed present in the nucleus. Furthermore, cytoplasmic GFP fluorescence intensity was similar between the two permeabilization conditions ($P = 0.86$; $n = 27$; t-test; Figure 2G), whereas nuclear GFP fluorescence intensity was significantly reduced in digitonin-permeabilised cells by 23 % ($P < 0.05$; $n = 27$; t-test; Figure 2G). Together, these data support the notion that there is a fraction of β 1-GFP signal which localises to the nucleus in MDA-MB-231- β 1-GFP cells.

We next studied co-localisation with specific organelle markers to further characterise the subcellular distribution of β 1-GFP. Given that β 1-GFP is a transmembrane protein, and an intracellular, punctate-like distribution is prominent in MDA-MB-231- β 1-GFP cells (Figure 2A), we hypothesised that β 1-GFP would be present within the endocytic pathway. Indeed, β 1-GFP partially colocalised with the early endosome marker EEA1 (Figure 3A, F), suggesting that it is present within early endosomes following internalisation. Similarly, β 1-GFP partially

colocalised with the lysosomal marker LAMP1 (Figure 3B, F), suggesting that it also progresses to lysosomes for degradation. To further confirm lysosomal expression of β 1-GFP, MDA-MB-231- β 1-GFP cells were treated with chloroquine, an inhibitor of lysosomal degradation. Chloroquine treatment caused a characteristic swelling and vacuolization of lysosomes (47), resulting in an accumulation of β 1-GFP within enlarged intracellular vesicles (Figure 3G). Cells were next labelled for marker proteins of the endoplasmic reticulum (calnexin), and *cis*- and *trans*-Golgi networks (GM130 and TGN46, respectively). β 1-GFP partially colocalised with GM130 (Figure 3C, F); however, there was a more robust overlap between β 1-GFP and TGN46 (Figure 3D, F) and calnexin (Figure 3E, F), suggesting that β 1-GFP is more abundant in the *trans*-Golgi network and endoplasmic reticulum than the *cis*-Golgi.

Effect of γ -secretase inhibition on β 1-GFP processing and function

Secretase cleavage remains an uncertain point of regulation for β 1, and it is not fully understood whether secretase cleavage influences β 1-mediated α subunit regulation. An α -subunit interaction site within the β 1-ICD, which is responsible for α -subunit surface trafficking, presents the possibility of secretase-mediated regulation of Na^+ current via β 1 (4). In addition, γ -secretase inhibition prevents β 2-mediated cell adhesion (38), and reduces β 1-mediated neurite outgrowth (3), suggesting that the CAM function of β 1 could also be regulated by secretase processing. To investigate these possibilities, we treated MDA-MB-231- β 1-GFP cells with the γ -secretase inhibitor, DAPT (Figure 4A). DAPT treatment reduced the amount of β 1ICD-GFP cleavage product present, increasing the C-terminal fragment (CTF):ICD expression ratio by 15-fold ($P < 0.01$; $n = 4-5$; t-test; Figure 4B). We next tested the effect of γ -secretase inhibition on Na^+ current in MDA-MB-231- β 1-GFP cells. Peak current density of MDA-MB-231- β 1-GFP cells treated with DAPT (-30.74 ± 3.21 pA/pF; $n = 10$) was no different to that of DMSO vehicle-treated cells (-26.89 ± 1.86 pA/pF; $P = 0.29$; n

= 12; t-test; Figure 4C). This result suggests that γ -secretase activity is not involved in the β 1-GFP-mediated increase in Na^+ current. We also tested the effect of two other γ -secretase inhibitors, L-685,458 and avagacestat. Both compounds reduced the amount of β 1ICD-GFP and increased the CTF:ICD expression ratio (Figure 4D). Similar to DAPT, avagacestat treatment had no effect on peak current density ($P = 0.11$; $n = 7-8$; t-test; Figure 4E). In contrast, L-685,458 (10 μM) did inhibit peak current density in MDA-MB-231- β 1-GFP cells ($P < 0.01$; $n = 8-18$; one-way ANOVA; Figure 4F, top sub-panel); however, it also inhibited peak current density in control MDA-MB-231-GFP cells ($P < 0.01$; $n = 8-18$; one-way ANOVA; Figure 4F, bottom sub-panel), suggesting the inhibition was independent of β 1-GFP. At a lower dose (1 μM), L-685,458 did not inhibit peak current density in either MDA-MB-231- β 1-GFP ($P = 0.69$; $n = 8-18$; one-way ANOVA; Figure 4F, top sub-panel) or MDA-MB-231-GFP cells ($P = 0.16$; $n = 8-18$; one-way ANOVA; Figure 4F, bottom sub-panel). None of the γ -secretase inhibitors affected channel recovery from inactivation (DAPT: $P = 0.25$, $n = 8$, t-test; avagacestat: $P = 0.29$, $n = 5-8$, t-test; L685,458: $P = 0.11$, $n = 8$, t-test; Figure 4G). In summary, pharmacological inhibition of γ -secretase caused a reduction in the level of the β 1-ICD cleavage product; however, it had no detectable effect on Na^+ current.

Effect of γ -secretase inhibition on β 1-GFP subcellular distribution

We next attempted to establish the subcellular site of secretase cleavage of β 1-GFP. γ -secretase is present throughout the cell, including the plasma membrane (48), nuclear envelope (49), endoplasmic reticulum (50), mitochondria (51), Golgi apparatus (52), endosomes (53), and lysosomes (54). Interestingly, following DAPT treatment, the Pearson's correlation coefficient (PCC) between β 1-GFP and EEA1 decreased by ~10 % ($P < 0.05$; $n = 25-26$; Mann-Whitney U-test; Figure 5A, C), suggesting a decrease in endosomal β 1-GFP following γ -secretase inhibition. There was no difference in the PCC between β 1-GFP and LAMP1 in vehicle- vs. DAPT-treated cells ($P = 0.44$; $n = 23 - 27$; Mann-Whitney U-test; Figure 5B, C), suggesting lysosomes may not be a site of secretase processing for β 1-GFP.

The observations that DAPT reduced the endosomal (but not lysosomal) $\beta 1$ -GFP level, and that the majority of $\beta 1$ -GFP is retained intracellularly (Figure 2), suggest that some $\beta 1$ -GFP may be trafficked to lysosomes for degradation without being expressed at the surface, as has been shown for amyloid precursor protein (APP) (55).

To obtain a better spatiotemporal understanding of γ -secretase-mediated cleavage of $\beta 1$ -GFP, we next followed GFP distribution in live MDA-MB-231- $\beta 1$ -GFP cells using confocal microscopy and fluorescence recovery after photobleaching (FRAP). Regions of interest (ROIs) were photobleached at the leading and trailing edges of control and DAPT-treated MDA-MB-231- $\beta 1$ -GFP cells (Figure 5D, E). Interestingly, no differences in the proportion of GFP that was freely mobile, or the time taken for half-maximal fluorescence recovery, were detected at the leading or trailing edges (Table 1). This result suggests that DAPT treatment had no effect on spatiotemporal cycling dynamics of $\beta 1$ -GFP.

Functional consequences of $\beta 1$ ICD-GFP overexpression

To further study the functional activity of the $\beta 1$ -ICD, we over-expressed $\beta 1$ ICD-GFP in MDA-MB-231 cells and measured its effect on Na^+ current using patch clamp recording (Figure 6A). Interestingly, $\beta 1$ -GFP-expressing cells (-11.7 ± 0.9 pA/pF) and $\beta 1$ ICD-GFP-expressing cells (-9.33 ± 1.0 pA/pF) displayed significantly larger Na^+ current density compared to control GFP-expressing cells (-4.36 ± 0.7 pA/pF; $P < 0.01$; $n = 14 - 16$; one-way ANOVA; Figure 6B). In addition, $\beta 1$ ICD-GFP accelerated the recovery from inactivation to the same extent as $\beta 1$ -GFP ($P < 0.05$; $n = 10$; one-way ANOVA; Figure 6C).

$\beta 1$ -GFP over-expression in MDA-MB-231 cells increases process length and decreases process width (32). We therefore next tested the effect $\beta 1$ ICD-GFP on cellular morphology.

β 1ICD-GFP overexpression had no effect on cell length ($P = 0.14$; $n = 150$; Kruskal-Wallis test; Figure 6D, E) or circularity ($P = 0.99$; $n = 150$; Kruskal-Wallis test; Figure 6D, E), relative to expression of GFP alone. In contrast β 1-GFP increased cell length by $\sim 30\%$ ($P < 0.0001$; $n = 150$; Kruskal-Wallis test; Figure 6D, E) and reduced circularity by $\sim 27\%$ relative to GFP control ($P < 0.0001$; $n = 150$; Kruskal-Wallis test; Figure 6D, E). Together, these data suggest that β 1ICD-GFP recapitulates the electrophysiological effects of full-length β 1-GFP on Na^+ current in MDA-MB-231 cells but does not itself promote changes in cellular morphology.

Subcellular distribution of β 1ICD-GFP

To determine the extent of β 1-ICD localisation to the nucleus, we imaged β 1ICD-GFP-, β 1-GFP- and GFP-expressing cells by confocal microscopy (Figure 6F). We used GFP-expressing cells as a control for stochastic movement of small proteins because GFP is known to diffuse throughout the cell, including into the nucleus (56). The nuclear signal for β 1ICD-GFP was higher than for β 1-GFP, consistent with not all full-length β 1-GFP being cleaved at steady state ($P < 0.0001$; $n = 14\text{--}17$; one-way ANOVA; Figure 6G). In addition, GFP and β 1ICD-GFP had similar nuclear:cytoplasmic signal density ratio ($P = 0.98$; Figure 6G). These data suggest that β 1ICD-GFP is present within the nucleus. However, it is possible that nuclear localisation of β 1ICD-GFP may be due to stochastic diffusion from the cytoplasm, similar to the case with GFP.

To more accurately evaluate whether β 1ICD-GFP distribution differs from GFP, we compared the mobility of both proteins using FRAP. Initially, a ROI within the cytoplasm of MDA-MB-231-GFP and MDA-MB-231- β 1ICD-GFP cells was photobleached and fluorescence recovery measured (Figure 7A, B). GFP and β 1ICD-GFP displayed similar mobility kinetics within the cytoplasm, with both proteins having a comparable mobile fraction

of ~ 1 ($P = 0.07$; $n = 15$; Mann-Whitney U-test; Figure 7C) and time taken for half maximal fluorescence recovery ($P = 0.13$; $n = 15$; Welch's t-test; Figure 7D). These data suggest that $\beta 1$ ICD-GFP and GFP have similar spatiotemporal expression within the cytoplasm of MDA-MB-231 cells.

Next, we compared the nuclear import kinetics of GFP and $\beta 1$ ICD-GFP. Other cleaved ICDs, such as APP, are trafficked to the nucleus as part of a heteromeric complex (57). Such a complex is expected to have slower import kinetics than soluble GFP, which can diffuse directly through nuclear pores. We labelled live cells with the nuclear dye, Hoechst 33342, and then photobleached the overlapping nuclear GFP fluorescence and measured fluorescence recovery over time (Figure 7E, F). Both GFP and $\beta 1$ ICD-GFP demonstrated a similar mobile fraction of ~ 1 ($P = 0.08$; $n = 10$; unpaired t-test; Figure 7G), suggesting negligible immobilised protein is present within the nucleus. However, the time taken for half-maximal fluorescence recovery was ~ 2.5 fold greater for $\beta 1$ ICD-GFP relative to GFP ($P < 0.001$; $n = 10$; Mann-Whitney U-test; Figure 7H), implying different nuclear import kinetics for both proteins. According to the experimentally verified cubic relationship between molecular weight and time taken for nuclear import, the five additional kilodaltons of $\beta 1$ ICD-GFP should increase diffusion time through nuclear pores by $\sim 70\%$ compared to GFP (58). Therefore, $\beta 1$ ICD-GFP may be entering the nucleus as part of a larger protein complex.

Effect of $\beta 1$ -GFP and $\beta 1$ ICD-GFP expression on tetrodotoxin sensitivity

To further evaluate the involvement of the ICD in regulating Na^+ current, we over-expressed $\beta 1$ STOP-GFP, which lacks the ICD (59), in MDA-MB-231 cells (Figure 8A). $\beta 1$ STOP-GFP did not significantly increase peak current density compared to GFP ($P = 0.89$; $n = 15$; one-way ANOVA; Figure 8B). This result underscores the importance of the $\beta 1$ ICD for increasing Na^+ current density. *SCN5A* mRNA constitutes 82 % of total α -subunit-encoding mRNA

present and the Na⁺ current in MDA-MB-231 cells is predominantly TTX-resistant, suggesting Na_v1.5 is the main α -subunit at the cell surface (43). Given that β 1-GFP and β 1ICD-GFP increased Na⁺ current, we used TTX to examine whether the composition of functional α subunits at the plasma membrane was altered, as 1 μ M TTX blocks Na_v1.1–1.4, Na_v1.6, and Na_v1.7, but not Na_v1.5. When perfused with 1 μ M TTX, the Na⁺ current in MDA-MB-231-GFP cells was not significantly altered ($P = 0.59$; $n = 9$; one-way ANOVA; Figure 8C, left panel), consistent with a TTX-resistant channel, most likely Na_v1.5, predominant at the cell surface. In MDA-MB-231- β 1-GFP cells, however, 1 μ M TTX significantly decreased the Na⁺ current by $33 \pm 2\%$ ($P < 0.0001$; $n = 9$; one-way ANOVA; Figure 8C, centre panel). In addition, 1 μ M TTX application also decreased Na⁺ current in β 1ICD-GFP-expressing cells by $35 \pm 3\%$ ($P < 0.0001$; $n = 9$; one-way ANOVA; Figure 8C, right panel). These data suggest that β 1-GFP and β 1ICD-GFP are both capable of increasing the proportion of TTX-sensitive α subunits at the plasma membrane.

Discussion

In this study, we show that both β 1-GFP and its γ -secretase cleavage product, β 1ICD-GFP, are functionally active in MDA-MB-231 breast cancer cells. We show that the majority of β 1-GFP is retained intracellularly, specifically within the endoplasmic reticulum, Golgi apparatus, endosomes, and lysosomes. A reduction in endosomal β 1-GFP level occurred following γ -secretase inhibition, implicating endosomes, and/or the preceding plasma membrane, as an important site for secretase processing. A small fraction of β 1-GFP was detected in the nucleus, and soluble β 1ICD-GFP demonstrated unique nuclear expression and import kinetics. Furthermore, β 1ICD-GFP was necessary and sufficient to increase Na⁺ current measured at the plasma membrane. Finally, both β 1-GFP and β 1ICD-GFP increased TTX sensitivity of the Na⁺ current. We therefore propose that the proteolytically released β 1ICD is

a critical regulator of α subunit function and expression. A strength of our study compared with previous studies (38,39,41), is that, by using GFP-tagged constructs, we were able to visualise $\beta 1/\beta 1$ ICD dynamics in live cells. However, a caveat with this approach is that we cannot exclude the possibility that the GFP tag may interfere with function of the native protein and its cleavage products. Nonetheless, our findings are generally consistent with these other reports, suggesting that any disruption of $\beta 1$ function by the GFP tag may be minor.

The requirement for $\beta 1$ insertion into the plasma membrane as a prerequisite for secretase processing is dependent on S-palmitoylation of a cysteine residue found at the transmembrane-intracellular interface of $\beta 1$ (40). Our work supports this finding and suggests that although secretase cleavage is not necessary for the $\beta 1$ -dependent increase of Na^+ current *per se*, presence of the $\beta 1$ -ICD is required. Previous work has demonstrated that the extracellular domain of $\beta 1$ is sufficient to accelerate channel inactivation in *Xenopus* oocytes (33,60), and more recent voltage clamp fluorimetry and protein crystallography studies have further shown interaction between $\beta 1$ and voltage-sensing domains of α subunits (7,35,36). Thus, a mechanistic understanding of how $\beta 1$ modulates α subunit gating and kinetics is becoming clearer. However, the mechanism underlying $\beta 1$ -mediated potentiation of VGSC expression at the plasma membrane and the consequent increase in current density remains uncertain. An interaction site within the $\beta 1$ -ICD is required to increase surface expression of $\text{Na}_v 1.1$ and $\text{Na}_v 1.2$ in heterologous cell models (4,34). Furthermore, the $\beta 1$ -ICD has been shown to increase $\text{Na}_v 1.8$ current density through deletion and $\beta 1$ - $\beta 2$ chimera experiments (61). Soluble, intracellular non-pore-forming subunits for other ion channel families also exist. For example, various $\text{Ca}_v \beta$, $\text{K}_v \beta$ and K^+ channel interacting protein (KChIP) subunits can modulate channel activation/inactivation kinetics and increase surface expression (in the case of $\text{Ca}_v \beta$ s and KChIPs) (62-65). Furthermore, the APP-ICD has been shown to increase $\text{Na}_v 1.6$ current when co-expressed

in *Xenopus* oocytes (66). Together, our data support the notion that the $\beta 1$ -ICD is a functionally active regulator of α subunit expression at the plasma membrane. However, the precise involvement of γ -secretase cleavage on these mechanisms appears complex, given that full-length $\beta 1$ -GFP and $\beta 1$ ICD-GFP both promote Na^+ current, and that pharmacological inhibition of γ -secretase activity had no effect. Furthermore, the $\beta 1$ -mediated targeting of α subunits to the plasma membrane may be cell type-specific (39). Further work is required to elucidate the context-dependent trafficking mechanisms involved.

Proteolytic processing is also an important regulator of the CAM function of β subunits in neurons and cancer cells. Pharmacological blockade of γ -secretase cleavage inhibits $\beta 1$ -mediated neurite outgrowth in cerebellar granule neurons (3). Additionally, γ -secretase inhibition decreases $\beta 2$ -induced transcellular adhesion and cell migration (38). The soluble cleaved extracellular Ig domains of $\beta 1$ and $\beta 4$, as well as the soluble splice variant $\beta 1B$, have been shown to promote neurite outgrowth (17,67,68). In MDA-MB-231 cells, $\beta 1$ -GFP, but not a mutant lacking the Ig domain, promotes neurite-like process outgrowth (31). In agreement with these observations, we found here that, in contrast to full-length $\beta 1$ -GFP, $\beta 1$ ICD-GFP was not capable of promoting process outgrowth in MDA-MB-231 cells. Thus, regulated proteolysis at the plasma membrane is likely to be a key mechanism by which the CAM function of $\beta 1$ is modulated to fine-tune neurite outgrowth, neuronal pathfinding, fasciculation and cell migration (11-17,40).

A number of secretase-cleaved ICDs have been shown to translocate to the nucleus and are involved in gene regulation, such as the ICDs for APP (69), CD44 (70) and Notch (71). The ICDs of $\beta 1$ and $\beta 2$ have been shown to accumulate in the nucleus of heterologous cells (39,41). In addition, the $\beta 2$ -ICD has been shown to upregulate *SCN1A*/ $\text{Na}_v 1.1$ mRNA and protein expression (41), raising the possibility that secretase cleavage may modulate α

subunit expression via altering α subunit transcription. Moreover, the $\beta 1$ -ICD has recently been shown to regulate the transcription of multiple genes (39). Our findings provide additional insight with respect to putative $\beta 1$ -ICD nuclear function, showing accumulation in the nucleus of live and fixed cells. In addition, although the endogenous Na^+ current in these cells is carried by $\text{Na}_v1.5$ (43,44), we observed an increase in TTX-sensitive current, suggesting increased expression and/or trafficking of different α subunits in the presence of $\beta 1$ -GFP and $\beta 1\text{ICD}$ -GFP. Further work is needed to determine how the $\beta 1$ -ICD is directed to the nucleus and the mechanism by which it regulates gene expression.

Taken together with the available literature (4,31,32,34,39-41), our data suggest that the $\beta 1$ -ICD promotes plasma membrane α subunit expression in breast cancer cells via several mechanisms (Figure 9). The observation that $\beta 1\text{STOP}$ -GFP failed to increase Na^+ current further identifies a requirement for the $\beta 1$ -ICD. $\beta 1\text{STOP}$ -GFP did, however, accelerate recovery from inactivation, suggesting that the $\beta 1$ -ICD is not required for regulation of α subunit inactivation kinetics. Therefore, it appears that the mechanisms underlying increased Na^+ current density, presumably via increased plasma membrane expression, and channel inactivation are distinct. Our data suggest that processing by γ -secretase may play a role in regulating $\beta 1$ function in breast cancer cells, adding to emerging evidence in other cell systems (39). The important role of γ -secretase activity in cancer progression (42), together with the growing evidence suggesting that $\beta 1\text{ICD}$ -mediated cellular changes promote pathologies including epilepsy, cardiac arrhythmia and cancer (39), further highlight the significance of this signalling axis to pathophysiologies associated with abnormal $\beta 1$ function.

Experimental Procedures

Cell culture

Human mammary carcinoma MDA-MB-231 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5 % (v/v) foetal bovine serum and 4 mM L-glutamine and cultured at 37 °C/ 5 % CO₂ (72). Stable MDA-MB-231-GFP and MDA-MB-231-β1-GFP cell lines were generated previously (32). Cell culture medium was supplemented with G418 (200 µg/ml, Sigma) for MDA-MB-231-GFP cells or Hygromycin B (100 µg/ml, Invitrogen) for the other transfected cell lines.

Pharmacology

γ-secretase inhibitors used in this study were as follows: avagacestat (10 µM, 24 h treatment time, Sigma), N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT) (1 µM, 24 h, Santa Cruz Biotech) and L-685,458 (1 - 10 µM, 24 h, Santa Cruz Biotech). DMSO was the vehicle for all drugs and DMSO concentration did not exceed 1:1000 at working concentration. Chloroquine (Tokyo Chemicals Industry) was dissolved in H₂O and used at 10 µM for 24 h.

Site-directed mutagenesis

A pEGFPN-1 expression plasmid encoding *Rattus norvegicus* β1, with a C-terminal enhanced GFP tag, was developed previously (32). The insert encoding β1-GFP was sub-cloned into a pcDNA3.1 expression vector (Invitrogen), following digest of 1 µg of both plasmids with 1 U of FastDigest NheI (Thermo) and FastDigest NotI (Thermo) for 30 min at 37°C. Fragments were gel purified (following kit instructions, Macherey-Nagel) and 30 ng of insert and 10 ng of vector ligated using 6U of T4 DNA ligase (Thermo, 1h, room temperature). pcDNA3.1-β1-GFP was used to produce several mutant β1 constructs using PCR-based site-directed mutagenesis following manufacturer's instructions (Phusion site-directed mutagenesis kit, Thermo) (31). β1 constructs produced were as follows: β1ICD-GFP (sequence starting at Tyr163 [mature protein amino acid numbering used, i.e. after 19

amino acid signal peptide cleaved]) and β 1STOP-GFP (β 1-ICD deletion, sequence terminated after Lys165), used previously (59). Primers used were as follows: β 1ICD-GFP forward- AAGAAGATTGCTGCTGCCACG and β 1ICD-GFP reverse- CATCTTGGGTCTCCCTATAGTGAGTCGTATTA (annealing temperature, T_A – 69 °C). β 1STOP-GFP forward – CGAATTCTGCAGTCG and β 1STOP-GFP reverse – CTTCTTGTAGCAGTACAC (T_A – 60 °C). All construct sequences were confirmed by Sanger sequencing (Source Bioscience).

Transfection and generation of stably transfected cell lines

MDA-MB-231 cells were transfected using jetPRIME (Polyplus) at a DNA:jetPRIME ratio (ng:nl) of 1:2. Medium was changed after 4 h. Stable cell lines were produced following Hygromycin B treatment (300 μ g/ml until non-transfected cells died) then ring selection and propagation of single colonies, maintained in Hygromycin B (100 μ g/ml).

Protein extraction and western blot

Protein extraction and western blotting were carried out as described previously, with some modifications (31). Total protein was extracted from a confluent 15 cm dish of cells and suspended in 50 mM Tris, 10 mM EGTA, with protease inhibitors (Roche). Lysates were diluted in Laemmli buffer at a ratio of 4:1 and heated at 80 °C for 10 min. Protein (30 – 100 μ g) was separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (12 % acrylamide, 120 V, 2 h) and transferred onto nitrocellulose membrane by semi-dry transfer (1.3 A, 25 V, 10 min). Primary antibodies were rabbit anti-GFP (ab6556, 1:2500, Abcam) or mouse anti- α -tubulin (clone DM1A, 1:10,000, Sigma). Secondary antibodies were HRP-conjugated goat anti-mouse (1:1000, Thermo Scientific) or goat anti-rabbit (1:1000, Thermo Scientific). Chemiluminescence was detected using an iBRIGHT imaging system (Invitrogen) or X-ray film (Fujifilm) following West Dura application (5 min, Thermo Scientific).

Densitometry was performed on western blot bands to estimate protein quantity using ImageJ 1.51i (73).

Morphology assay

10,000 cells were seeded into a well of a 24-well plate and left for 72 h prior to image acquisition. Cells were fixed using 4 % (w/v) paraformaldehyde (PFA) in PBS at room temperature for 10 min and washed with 0.1 M phosphate buffer (PB, 81 mM Na₂HPO₄, 19 mM NaH₂PO₄, pH 7.4). Five brightfield images of each well were acquired, as well as GFP images to ensure construct expression. Images were exported to ImageJ for analysis. Cell morphology was assessed by manually masking the first 50 randomly selected cells and measuring circularity and Feret's diameter (estimator of cell length) using the in-built analysis ImageJ plugin. The experiment was repeated three times.

Immunocytochemistry

Protocols were adapted from (16,74). Cells grown on 13 mm glass coverslips were fixed with 4 % (w/v) PFA (dissolved in PBS) for 5 min and washed three times in 0.1 M PB. In some experiments, cells were incubated in 50 µg/ml digitonin (Santa Cruz Biotechnology) for 15 min and Triton X-100 was omitted in the subsequent steps (46). Depending on the primary antibody, cells were blocked for 1 h in either PBTGS (0.3 % (v/v) Triton X-100 and 10 % (v/v) normal goat serum in 0.1 M PB) for anti-Lamin B2 and anti-GFP antibodies, or BPS (0.5 % (w/v) BSA and 0.05 % (w/v) saponin dissolved in 0.1 M PB) for all other antibodies. Primary antibody (diluted in blocking solution) was applied for 1 h (antibodies diluted in BPS) or overnight (antibodies diluted in PBTGS). The following primary antibodies were used: anti-GFP (mouse, Neuromab, clone N86/38, 1:1000), anti-Lamin B2 (mouse, Invitrogen, clone E-3, 1:500), anti-EEA1 (mouse, clone 14/EEA1, BD Bioscience, 1:500), anti-LAMP1 (mouse, Biolegend, clone H4A3, 1:1000), anti-calnexin (mouse, BD Bioscience, clone 37/CNX, 1:50)

and anti-TGN46 (rabbit, Proteintech, 1:1000). Cells were then incubated in goat anti-mouse Alexa Fluor 568, or goat anti-rabbit Alexa Fluor 568 or 647 (1:500 in blocking solution, Thermo) for 1 h (antibodies diluted in BPS) or 2 h (antibodies diluted in PBTGS). Cells were incubated in 500 ng/ml 4',6-diamidino-2-phenylindole (DAPI, diluted in 0.1 M PB, Sigma, 10 min) prior to mounting using Prolong Gold (Invitrogen).

Confocal microscopy

Images were acquired using a Zeiss LSM 880 laser-scanning confocal microscope with Airyscan technology, using a Plan-Apochromat 63x oil immersion objective lens (NA = 1.4), controlled by ZEN2 software. The pinhole was set to 1.25 airy unit (AU) for Airyscan imaging and optimal resolution for Airyscan acquisition maintained (~29.41 pixels/μm) regardless of frame size (17.8 – 73.2 μm, depending on experiment). An automatic Airyscan processing strength of 6.0 was applied to the image post-acquisition. Ten images were acquired per experiment and the experiment repeated three times.

Nuclear localisation analysis

The nuclear:cytoplasmic mean GFP fluorescence intensity ratio was calculated from confocal images using the standard ImageJ toolkit. Nuclear fluorescence was calculated by masking the DAPI signal and measuring GFP fluorescence within the mask, both mean fluorescence intensity and total fluorescence. Mean cytoplasmic fluorescence intensity was calculated by subtracting total cellular GFP fluorescence by total nuclear GFP fluorescence and dividing the resulting value by the difference in area of the whole cell and nucleus.

Co-localisation analysis

To quantify the co-localisation between GFP and subcellular markers (Calnexin, GM130, TGN46, EEA1 or LAMP1), Pearson's correlation coefficient was calculated using the "Coloc 2" plugin in Fiji (ImageJ 1.51i) (75). First, images were split into GFP and marker channels and a region of interest (ROI) drawn around the cell using the GFP channel. Coloc2 was initiated using bisection threshold regression, a PSF of 3.0 pixels and a Costes randomisation value of 10. To analyse GFP overlap with the membrane marker FM4-64, line profiles were used. Ten-pixel wide, 5 μ m-long line profiles were placed, with the membrane marker centred at 2.5 μ m. Two to four line profiles were taken per cell and averaged. Fluorescence intensity was normalised to the maximum value for each cell. Ten cells were measured.

Live cell imaging, fluorescence recovery after photobleaching (FRAP) and Förster resonance energy transfer (FRET) acquisition

10,000 cells were seeded per well into an 8-well Lab-Tek II chambered coverglass slide (Nunc) 48 h prior to imaging. In some experiments, FM4-64 (Thermo, 120 nM) or Hoechst 33342 (Thermo, 1 μ g/ml) were applied immediately prior to imaging. FRAP acquisition was carried out using a Zeiss LSM 880 confocal microscope, with a Plan-Apochromat 63x oil immersion objective lens (NA = 1.4), controlled by ZEN2 software at 37 °C/5 % CO₂. GFP was imaged using a 488 nm laser (1 – 5 % laser power), using bidirectional scanning at maximum scan speed and a 1 AU pinhole.

To monitor FRAP in the cytoplasm, a single cell was imaged at 10x zoom factor with a 256 x 256-pixel frame size. A 1 μ m-wide ROI was photobleached with 40 iterations of a 488 nm laser (100 % laser power) and images acquired every 250 ms for 37.5 s. Alternatively, for a higher temporal resolution, a 64 x 64-pixel frame was used, and images acquired every 12.8 ms. Ten cells were imaged per experiment and three repeats performed.

To monitor FRAP in the nucleus, cells were imaged at 2.0x zoom factor with a 512 x 512-pixel frame size. A ROI was manually drawn around the nucleus (stained by Hoechst 33342) and photobleached with 40 iterations of the 488 nm laser (100 % laser power). Images were taken every 5 s until 10 successive images without an increase in nuclear fluorescence were acquired (typically 5 – 10 min). Three to four cells were imaged per experiment and the experiment repeated three times.

For FRET, cells were imaged at 2.0 – 4.0x zoom factor using a 512 x 512-pixel frame size. FM4-64 was bleached using 100 iterations of the 561 nm laser (100 % laser power) at the plasma membrane or within internal vesicles. Images were acquired every 0.6 s for 25 s.

FRAP analysis

Analysis for FRAP data was adapted from (76). Images were exported to ImageJ for data acquisition using the FRAP Norm plugin. Three regions were plotted on the image: the photobleached ROI, delineated as the full width at half maximum of the encompassing cytoplasmic GFP fluorescence or the entire photobleached nucleus, for cytoplasmic and nuclear photobleaching experiments, respectively. A control region, placed elsewhere in the cell, was used to calculate the rate of photobleaching at each time point across the time series, relative to the maximal fluorescence intensity at $t = 0$. Lastly, a background region was placed outside the cell, which was subtracted from the other two regions at each time point. Therefore, at each time point, the ROI could be normalised to the photobleaching rate. Finally, fluorescence intensity within the ROI was normalised to pre-bleach fluorescence intensity to obtain the final recovery curve. Two parameters were derived from these recovery curves to quantify mobility. The mobile fraction, which defines the proportion of fluorescent protein that is mobile relative to the whole population of fluorescent protein initially in the ROI, was calculated using:

$$\text{mobile fraction} = \frac{F_{\text{final}} - F_0}{F_i - F_0}$$

Where F_{final} = final fluorescence measurement, F_0 = first post-bleach fluorescence measurement, and F_i = pre-bleach fluorescence measurement. The half-time describes the time taken for half maximal fluorescence recovery and was derived from a single exponential curve fitted to post-bleach measurements.

FRET analysis

To analyse FRET, images were exported to ImageJ and analysed using the FRAP Norm plugin. GFP and FM4-64 fluorescence intensities were monitored within the photobleaching ROI for the duration of the time series and normalised against $t = 0$. FM4-64 signal was monitored to ensure photobleaching occurred. GFP fluorescence intensity before and after photobleaching was then statistically compared.

Whole cell patch clamp recording

Whole cell patch clamp recordings were performed and analysed as described previously (77). Data were collected at a sampling rate of 50 kHz and filtered at 10 kHz. Linear leak currents were removed using P/6 subtraction (78). Series resistance was compensated by 40 %. Extracellular recording solution (physiological saline solution; PSS) contained (in mM): 144 NaCl, 5.4 KCl, 1 MgCl₂, 2.5 CaCl₂, 5 HEPES, 5.6 D-glucose, adjusted to pH 7.2 with KOH. For experiments involving cells pre-treated with drugs, the drug or vehicle was included in the PSS. The intracellular patch pipette solution contained (in mM): 5 NaCl, 145 CsCl, 2 MgCl₂, 1 CaCl₂, 10 HEPES and 11 EGTA, adjusted to pH 7.4 using CsOH. To assess current-voltage (I-V) relationships and activation-voltage relationships, cells were pre-pulsed at -120 mV for 250 ms before 5 mV depolarising steps for 50 ms in the range -80 mV to +30 mV. Steady-state inactivation was assessed at -10 mV for 50 ms following conditioning pre-pulse steps for 250 ms in the range -120 mV to -10 mV. Recovery from

inactivation was assessed following depolarisation to 0 mV for 25 ms, holding at -120 mV for t ms, then second depolarisation at 0 mV for 25 ms. t : 1, 2, 3, 5, 7, 10, 15, 20, 30, 40, 50, 70, 100, 150, 200, 250, 350, 500 ms. In experiments involving TTX perfusion, TTX solution (1 μ M in PSS) was exchanged for PSS (and vice versa) by performing three bath changes, with voltage clamp protocols run in each condition.

Data analysis

GraphPad Prism 8.0 was used for all curve fitting and statistical analyses. Normality of data was initially assessed using a D'Agostino and Pearson test. For normally distributed data, an unpaired Student's t-test was used for pairwise comparisons and a one-way ANOVA with Tukey's post hoc test used for multiple comparisons and data presented as mean $\pm$ SEM. For data not following a normal distribution, pairwise comparisons were performed using a Mann-Whitney U-test and multiple comparisons were performed using a Kruskal-Wallis test with Dunn's multiple comparison post hoc test. Results were considered significant if $P < 0.05$.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Acknowledgements

The authors thank Michaela Nelson for technical assistance with establishing the cellular assays and the University of York Bioscience Technology Facility for their support with the confocal microscopy.

Author contributions

AH, CB and WB contributed to the conception and design of the work. ASH, SLH, LLI, CGB and WJB contributed to acquisition, analysis, and interpretation of data for the work. ASH, SLH, LLI, CGB and WJB contributed to drafting the work and revising it critically for important intellectual content. All authors approved the final version of the manuscript.

Funding

This work was supported by a studentship from the BBSRC Doctoral Training Partnership in “Mechanistic Biology and its Strategic Application” Grant BB/M011151/1 to ASH, CGB and WJB, by NIH R37 NS076752 to LLI, and by a University of Michigan Postdoctoral Pioneer Program Fellowship to SLH.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Catterall, W. A. (2014) Structure and function of voltage-gated sodium channels at atomic resolution. *Exp. Physiol.* **99**, 35-51
2. Hille, B. (1992) *Ionic channels of excitable membranes*, 2nd ed., Sinauer Associates Inc., Sunderland (Massachusetts)
3. Brackenbury, W. J., and Isom, L. L. (2011) Na Channel β Subunits: Overachievers of the Ion Channel Family. *Front Pharmacol* **2**, 53
4. Meadows, L., Malhotra, J. D., Stetzer, A., Isom, L. L., and Ragsdale, D. S. (2001) The intracellular segment of the sodium channel beta 1 subunit is required for its efficient association with the channel alpha subunit. *J Neurochem* **76**, 1871-1878
5. Isom, L. L., Scheuer, T., Brownstein, A. B., Ragsdale, D. S., Murphy, B. J., and Catterall, W. A. (1995) Functional co-expression of the beta 1 and type IIA alpha subunits of sodium channels in a mammalian cell line. *J Biol Chem* **270**, 3306-3312
6. Isom, L. L., De Jongh, K. S., Patton, D. E., Reber, B. F., Offord, J., Charbonneau, H., Walsh, K., Goldin, A. L., and Catterall, W. A. (1992) Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. *Science (New York, N. Y.)* **256**, 839-842

7. Zhu, W., Voelker, T. L., Varga, Z., Schubert, A. R., Nerbonne, J. M., and Silva, J. R. (2017) Mechanisms of noncovalent beta subunit regulation of NaV channel gating. *J. Gen. Physiol.* **149**, 813-831
8. Korner, J., Meents, J., Machtens, J. P., and Lampert, A. (2018) beta1 subunit stabilises sodium channel Nav1.7 against mechanical stress. *J. Physiol.* **596**, 2433-2445
9. Maroni, M., Korner, J., Schuttler, J., Winner, B., Lampert, A., and Eberhardt, E. (2019) beta1 and beta3 subunits amplify mechanosensitivity of the cardiac voltage-gated sodium channel Nav1.5. *Pflugers Arch.* **471**, 1481-1492
10. Laedermann, C. J., Syam, N., Pertin, M., Decosterd, I., and Abriel, H. (2013) beta1- and beta3- voltage-gated sodium channel subunits modulate cell surface expression and glycosylation of Nav1.7 in HEK293 cells. *Front. Cell. Neurosci.* **7**, 137
11. McEwen, D. P., and Isom, L. L. (2004) Heterophilic interactions of sodium channel beta1 subunits with axonal and glial cell adhesion molecules. *J. Biol. Chem.* **279**, 52744-52752
12. Xiao, Z. C., Ragsdale, D. S., Malhotra, J. D., Mattei, L. N., Braun, P. E., Schachner, M., and Isom, L. L. (1999) Tenascin-R is a functional modulator of sodium channel beta subunits. *J. Biol. Chem.* **274**, 26511-26517
13. Malhotra, J. D., Kazen-Gillespie, K., Hortsch, M., and Isom, L. L. (2000) Sodium channel subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact. *J. Biol. Chem.* **275**, 11383-11388
14. Kazarinova-Noyes, K., Malhotra, J. D., McEwen, D. P., Mattei, L. N., Berglund, E. O., Ranscht, B., Levinson, S. R., Schachner, M., Shrager, P., Isom, L. L., and Xiao, Z.-C. (2001) Contactin associates with Na⁺ channels and increases their functional expression. *J. Neurosci.* **21**, 7517-7525
15. Brackenbury, W. J., Yuan, Y., O'Malley, H. A., Parent, J. M., and Isom, L. L. (2013) Abnormal neuronal patterning occurs during early postnatal brain development of Scn1b-null mice and precedes hyperexcitability. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 1089-1094
16. Brackenbury, W. J., Calhoun, J. D., Chen, C., Miyazaki, H., Nukina, N., Oyama, F., Ranscht, B., and Isom, L. L. (2010) Functional reciprocity between Na⁺ channel Nav1.6 and beta1 subunits in the coordinated regulation of excitability and neurite outgrowth. *Proc Natl Acad Sci U S A* **107**, 2283-2288
17. Davis, T. H., Chen, C., and Isom, L. L. (2004) Sodium channel beta1 subunits promote neurite outgrowth in cerebellar granule neurons. *J. Biol. Chem.* **279**, 51424-51432
18. Brackenbury, W. J., Davis, T. H., Chen, C., Slat, E. A., Detrow, M. J., Dickendesher, T. L., Ranscht, B., and Isom, L. L. (2008) Voltage-gated Na⁺ channel β1 subunit-mediated neurite outgrowth requires fyn kinase and contributes to central nervous system development in vivo. *J. Neurosci.* **28**, 3246-3256
19. Malhotra, J., Chen, C., Rivolta, I., Abriel, H., Malhotra, R., Mattei, L. N., Brosius, F. C., Kass, R. S., and Isom, L. L. (2001) Characterization of sodium channel alpha- and beta-subunits in rat and mouse cardiac myocytes. *Circulation* **103**, 1303-1310
20. Malhotra, J. D., Koopmann, M. C., Kazen-Gillespie, K. A., Fettman, N., Hortsch, M., and Isom, L. L. (2002) Structural requirements for interaction of sodium channel b1 subunits with ankyrin. *J. Biol. Chem.* **277**, 26681-26688.
21. Rivaud, M. R., Delmar, M., and Remme, C. A. (2020) Heritable arrhythmia syndromes associated with abnormal cardiac sodium channel function: ionic and non-ionic mechanisms. *Cardiovasc. Res.* **116**, 1557-1570
22. Kaplan, D. I., Isom, L. L., and Petrou, S. (2016) Role of Sodium Channels in Epilepsy. *Cold Spring Harb. Perspect. Med.* **6**
23. Aeby, A., Sculier, C., Bouza, A. A., Askar, B., Lederer, D., Schoonjans, A. S., Vander Ghinst, M., Ceulemans, B., Offord, J., Lopez-Santiago, L. F., and Isom, L. L. (2019) SCN1B-linked early infantile developmental and epileptic encephalopathy. *Ann Clin Transl Neurol* **6**, 2354-2367

24. Bouza, A. A., and Isom, L. L. (2018) Voltage-Gated Sodium Channel β Subunits and Their Related Diseases. *Handb. Exp. Pharmacol.* **246**
25. Watanabe, H., Darbar, D., Kaiser, D. W., Jiramongkolchai, K., Chopra, S., Donahue, B. S., Kannankeril, P. J., and Roden, D. M. (2009) Mutations in Sodium Channel 1- and 2-Subunits Associated With Atrial Fibrillation. *Circ Arrhythmia Electrophysiol* **2**, 268-275
26. Watanabe, H., Koopmann, T. T., Le Scouarnec, S., Yang, T., Ingram, C. R., Schott, J. J., Demolombe, S., Probst, V., Anselme, F., Escande, D., Wiesfeld, A. C., Pfeufer, A., Kaab, S., Wichmann, H. E., Hasdemir, C., Aizawa, Y., Wilde, A. A., Roden, D. M., and Bezzina, C. R. (2008) Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. *J. Clin. Invest.* **118**, 2260-2268
27. Chen, C., Westenbroek, R. E., Xu, X., Edwards, C. A., Sorenson, D. R., Chen, Y., McEwen, D. P., O'Malley, H. A., Bharucha, V., Meadows, L. S., Knudsen, G. A., Vilaythong, A., Noebels, J. L., Saunders, T. L., Scheuer, T., Shrager, P., Catterall, W. A., and Isom, L. L. (2004) Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. *J. Neurosci.* **24**, 4030-4042
28. Veeraraghavan, R., Hoeker, G. S., Alvarez-Laviada, A., Hoagland, D., Wan, X., King, D. R., Sanchez-Alonso, J., Chen, C., Jourdan, J., Isom, L. L., Deschenes, I., Smyth, J. W., Gorelik, J., Poelzing, S., and Gourdie, R. G. (2018) The adhesion function of the sodium channel beta subunit (beta1) contributes to cardiac action potential propagation. *Elife* **7**
29. Lopez-Santiago, L. F., Meadows, L. S., Ernst, S. J., Chen, C., Malhotra, J. D., McEwen, D. P., Speelman, A., Noebels, J. L., Maier, S. K., Lopatin, A. N., and Isom, L. L. (2007) Sodium channel Scn1b null mice exhibit prolonged QT and RR intervals. *J. Mol. Cell. Cardiol.* **43**, 636-647
30. Djamgoz, M. B. A., Fraser, S. P., and Brackenbury, W. J. (2019) In Vivo Evidence for Voltage-Gated Sodium Channel Expression in Carcinomas and Potentiation of Metastasis. *Cancers (Basel)* **11**
31. Nelson, M., Millican-Slater, R., Forrest, L. C., and Brackenbury, W. J. (2014) The sodium channel β 1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes tumour growth and metastasis. *Int J Cancer* **135**, 2338-2351
32. Chioni, A. M., Brackenbury, W. J., Calhoun, J. D., Isom, L. L., and Djamgoz, M. B. (2009) A novel adhesion molecule in human breast cancer cells: voltage-gated Na⁺ channel beta1 subunit. *Int J Biochem Cell Biol* **41**, 1216-1227
33. McCormick, K. A., Srinivasan, J., White, K., Scheuer, T., and Catterall, W. A. (1999) The extracellular domain of the beta1 subunit is both necessary and sufficient for beta1-like modulation of sodium channel gating. *J Biol Chem* **274**, 32638-32646
34. Spanpanato, J., Kearney, J. A., de Haan, G., McEwen, D. P., Escayg, A., Aradi, I., MacDonald, B. T., Levin, S. I., Soltesz, I., Benna, P., Montalenti, E., Isom, L. L., Goldin, A. L., and Meisler, M. H. (2004) A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. *J Neurosci* **24**, 10022-10034
35. Pan, X., Li, Z., Zhou, Q., Shen, H., Wu, K., Huang, X., Chen, J., Zhang, J., Zhu, X., Lei, J., Xiong, W., Gong, H., Xiao, B., and Yan, N. (2018) Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1. *Science* **362**
36. Yan, Z., Zhou, Q., Wang, L., Wu, J., Zhao, Y., Huang, G., Peng, W., Shen, H., Lei, J., and Yan, N. (2017) Structure of the Nav1.4-beta1 Complex from Electric Eel. *Cell* **170**, 470-482.e411
37. Wong, H.-K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., and Nukina, N. (2005) beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. *J Biol Chem* **280**, 23009-23017

38. Kim, D. Y., Ingano, L. A. M., Carey, B. W., Pettingell, W. H., and Kovacs, D. M. (2005) Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. *J Biol Chem* **280**, 23251-23261
39. Bouza, A. A., Edokobi, N., Hodges, S. L., Pinsky, A. M., Offord, J., Piao, L., Zhao, Y. T., Lopatin, A. N., Lopez-Santiago, L. F., and Isom, L. L. (2021) Sodium channel beta1 subunits participate in regulated intramembrane proteolysis-excitation coupling. *JCI Insight* **6**
40. Bouza, A. A., Philippe, J. M., Edokobi, N., Pinsky, A. M., Offord, J., Calhoun, J. D., Lopez-Floran, M., Lopez-Santiago, L. F., Jenkins, P. M., and Isom, L. L. (2020) Sodium channel beta1 subunits are post-translationally modified by tyrosine phosphorylation, S-palmitoylation, and regulated intramembrane proteolysis. *J. Biol. Chem.* **295**, 10380-10393
41. Kim, D. Y., Carey, B. W., Wang, H., Ingano, L. A. M., Binshtok, A. M., Wertz, M. H., Pettingell, W. H., He, P., Lee, V. M.-Y., Woolf, C. J., and Kovacs, D. M. (2007) BACE1 regulates voltage-gated sodium channels and neuronal activity. *Nat Cell Biol* **9**, 755-764
42. Ran, Y., Hossain, F., Pannuti, A., Lessard, C. B., Ladd, G. Z., Jung, J. I., Minter, L. M., Osborne, B. A., Miele, L., and Golde, T. E. (2017) gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. *EMBO Mol. Med.* **9**, 950-966
43. Fraser, S. P., Diss, J. K., Chioni, A. M., Mycielska, M. E., Pan, H., Yamaci, R. F., Pani, F., Siwy, Z., Krasowska, M., Grzywna, Z., Brackenbury, W. J., Theodorou, D., Koyuturk, M., Kaya, H., Battaloglu, E., De Bella, M. T., Slade, M. J., Tolhurst, R., Palmieri, C., Jiang, J., Latchman, D. S., Coombes, R. C., and Djamgoz, M. B. (2005) Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. *Clin Cancer Res* **11**, 5381-5389
44. Brackenbury, W. J., Chioni, A. M., Diss, J. K., and Djamgoz, M. B. (2007) The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. *Breast Cancer Res. Treat.* **101**, 149-160
45. Dulsat, G., Palomeras, S., Cortada, E., Riuro, H., Brugada, R., and Verges, M. (2017) Trafficking and localisation to the plasma membrane of Nav 1.5 promoted by the beta2 subunit is defective due to a beta2 mutation associated with Brugada syndrome. *Biol Cell* **109**, 273-291
46. Mojica, S. A., Hovis, K. M., Frieman, M. B., Tran, B., Hsia, R. C., Ravel, J., Jenkins-Houk, C., Wilson, K. L., and Bavoi, P. M. (2015) SINC, a type III secreted protein of *Chlamydia psittaci*, targets the inner nuclear membrane of infected cells and uninfected neighbors. *Mol Biol Cell* **26**, 1918-1934
47. Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K. J., Coppes, R. P., Engedal, N., Mari, M., and Reggiori, F. (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy* **14**, 1435-1455
48. Chyung, J. H., Raper, D. M., and Selkoe, D. J. (2005) Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. *J Biol Chem* **280**, 4383-4392
49. Kimura, N., Nakamura, S. I., Honda, T., Takashima, A., Nakayama, H., Ono, F., Sakakibara, I., Doi, K., Kawamura, S., and Yoshikawa, Y. (2001) Age-related changes in the localization of presenilin-1 in cynomolgus monkey brain. *Brain Res* **922**, 30-41
50. Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J., and Selkoe, D. J. (1998) Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. *Biochemistry* **37**, 16465-16471
51. Area-Gomez, E., de Groof, A. J., Boldogh, I., Bird, T. D., Gibson, G. E., Koehler, C. M., Yu, W. H., Duff, K. E., Yaffe, M. P., Pon, L. A., and Schon, E. A. (2009)

- Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. *Am J Pathol* **175**, 1810-1816
52. Zhang, J., Kang, D. E., Xia, W., Okochi, M., Mori, H., Selkoe, D. J., and Koo, E. H. (1998) Subcellular distribution and turnover of presenilins in transfected cells. *J Biol Chem* **273**, 12436-12442
 53. Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., and Thinakaran, G. (2004) Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. *J Biol Chem* **279**, 44945-44954
 54. Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J. W., and Mahuran, D. J. (2003) Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. *J Biol Chem* **278**, 26687-26694
 55. Tam, J. H., Seah, C., and Pasternak, S. H. (2014) The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid. *Mol Brain* **7**, 54
 56. Seibel, N. M., Eljouni, J., Nalaskowski, M. M., and Hampe, W. (2007) Nuclear localization of enhanced green fluorescent protein homomultimers. *Anal Biochem* **368**, 95-99
 57. Cao, X., and Sudhof, T. C. (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science (New York, N.Y.)* **293**, 115-120
 58. Timney, B. L., Raveh, B., Mironska, R., Trivedi, J. M., Kim, S. J., Russel, D., Wentz, S. R., Sali, A., and Rout, M. P. (2016) Simple rules for passive diffusion through the nuclear pore complex. *J Cell Biol* **215**, 57-76
 59. McCormick, K. A., Isom, L. L., Ragsdale, D., Smith, D., Scheuer, T., and Catterall, W. A. (1998) Molecular determinants of Na⁺ channel function in the extracellular domain of the beta1 subunit. *J. Biol. Chem.* **273**, 3954-3962
 60. Makita, N., Bennett, P. B., and George, A. L., Jr. (1996) Molecular determinants of beta 1 subunit-induced gating modulation in voltage-dependent Na⁺ channels. *J. Neurosci.* **16**, 7117-7127
 61. Chahine, M., and O'Leary, M. E. (2011) Regulatory Role of Voltage-Gated Na Channel β Subunits in Sensory Neurons. *Front Pharmacol* **2**, 70
 62. Pragnell, M., De Waard, M., Mori, Y., Tanabe, T., Snutch, T. P., and Campbell, K. P. (1994) Calcium channel beta-subunit binds to a conserved motif in the I-II cytoplasmic linker of the alpha 1-subunit. *Nature* **368**, 67-70
 63. An, W. F., Bowlby, M. R., Betty, M., Cao, J., Ling, H. P., Mendoza, G., Hinson, J. W., Mattsson, K. I., Strassle, B. W., Trimmer, J. S., and Rhodes, K. J. (2000) Modulation of A-type potassium channels by a family of calcium sensors. *Nature* **403**, 553-556
 64. Yang, E. K., Alvira, M. R., Levitan, E. S., and Takimoto, K. (2001) Kvbeta subunits increase expression of Kv4.3 channels by interacting with their C termini. *J Biol Chem* **276**, 4839-4844
 65. Altier, C., Garcia-Caballero, A., Simms, B., You, H., Chen, L., Walcher, J., Tedford, H. W., Hermosilla, T., and Zamponi, G. W. (2011) The Cavbeta subunit prevents RFP2-mediated ubiquitination and proteasomal degradation of L-type channels. *Nat Neurosci* **14**, 173-180
 66. Li, S., Wang, X., Ma, Q. H., Yang, W. L., Zhang, X. G., Dawe, G. S., and Xiao, Z. C. (2016) Amyloid precursor protein modulates Nav1.6 sodium channel currents through a Go-coupled JNK pathway. *Sci Rep* **6**, 39320
 67. Miyazaki, H., Oyama, F., Wong, H. K., Kaneko, K., Sakurai, T., Tamaoka, A., and Nukina, N. (2007) BACE1 modulates filopodia-like protrusions induced by sodium channel beta4 subunit. *Biochem Biophys Res Commun* **361**, 43-48
 68. Patino, G. A., Brackenbury, W. J., Bao, Y. Y., Lopez-Santiago, L. F., O'Malley, H. A., Chen, C. L., Calhoun, J. D., Lafreniere, R. G., Cossette, P., Rouleau, G. A., and Isom, L. L. (2011) Voltage-Gated Na⁺ Channel beta 1B: A Secreted Cell Adhesion Molecule Involved in Human Epilepsy. *J. Neurosci.* **31**, 14577-14591

69. Kimberly, W. T., Zheng, J. B., Guenette, S. Y., and Selkoe, D. J. (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. *J Biol Chem* **276**, 40288-40292
70. Okamoto, I., Kawano, Y., Murakami, D., Sasayama, T., Araki, N., Miki, T., Wong, A. J., and Saya, H. (2001) Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. *J Cell Biol* **155**, 755-762
71. Schroeter, E. H., Kisslinger, J. A., and Kopan, R. (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature* **393**, 382-386
72. Yang, M., Kozminski, D. J., Wold, L. A., Modak, R., Calhoun, J. D., Isom, L. L., and Brackenbury, W. J. (2012) Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. *Breast Cancer Res Treat* **134**, 603-615
73. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671-675
74. Roife, A. P., Davis, L. J., Whittingham, J. L., Latimer-Bowman, E. C., Wilkinson, A. J., and Pryor, P. R. (2017) The *Rhodococcus equi* virulence protein VapA disrupts endolysosome function and stimulates lysosome biogenesis. *MicrobiologyOpen* **6**
75. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., and Cardona, A. (2012) Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676-682
76. Phair, R. D., Gorski, S. A., and Misteli, T. (2004) Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. *Methods Enzymol* **375**, 393-414
77. Yang, M., James, A. D., Suman, R., Kasproicz, R., Nelson, M., O'Toole, P. J., and Brackenbury, W. J. (2020) Voltage-dependent activation of Rac1 by Nav 1.5 channels promotes cell migration. *J. Cell. Physiol.* **235**, 3950-3972
78. Armstrong, C. M., and Bezanilla, F. (1977) Inactivation of the sodium channel. II. Gating current experiments. *J. Gen. Physiol.* **70**, 567-590

Table 1. Mobility parameters of $\beta 1$ -GFP at the leading and trailing edges of MDA-MB-231 cells following DAPT treatment

	Leading edge		Trailing edge	
	DMSO	DAPT	DMSO	DAPT
Mobile fraction	0.73 ± 0.04	0.74 ± 0.04	0.79 ± 0.04	0.71 ± 0.05
	P = 0.55		P = 0.19	
Half-time (s)	2.55 ± 0. 0.16	2.43 ± 0.17	2.70 ± 0.20	2.64 ± 0.15
	P = 0.60		P = 0.82	
Comparisons between DMSO-DAPT treatment for each parameter at each location made using a Mann-Whitney U-test, P value displayed underneath each comparison. Data displayed as mean ± SEM. n = 25 – 28, N = 3. Abbreviations: half-time: time taken for half-maximal fluorescence recovery.				

Figure Legends

Figure 1. Electrophysiological properties of MDA-MB-231- β 1-GFP cells. (A) Representative whole-cell Na^+ currents in MDA-MB-231-GFP and MDA-MB-231- β 1-GFP cells, following depolarisation between -80 mV and +30 mV for 250 ms from -120 mV. (B) Peak current density (PCD). (C) Current (I)-voltage (V) relationship. (D) Conductance (G)-voltage (V) relationship. (E) voltage at activation (V_a). (F) voltage at half-maximal activation ($V_{1/2\text{-act}}$). (G) Slope factor of activation ($k - \text{act}$). (H) Voltage at peak current (V_p). (I) Steady-state inactivation. Cells were depolarised at -10 mV following a 250 ms holding voltage of between -80 mV and +30 mV. (J) Voltage at half-maximal inactivation ($V_{1/2\text{-inact}}$). (K) Slope factor of inactivation ($k - \text{inact}$). (L) Time to peak at 0 mV (T_p). (M) Whole cell capacitance (C_m). (N) Recovery from inactivation. Cells were depolarised to 0 mV for 25 ms, then held at -120 mV for t s before second depolarisation to 0 mV. t ranged from 1-500 ms. (O) time taken for half-maximal recovery. Data are presented as mean $\pm$ SEM ($n = 8$, $N = 3$). Activation and inactivation curves are fitted with a Boltzmann function. ns = not significant, * = $P < 0.05$, ** = $P < 0.01$, unpaired t-test.

Figure 2. Plasma membrane and nuclear localisation of β 1-GFP. (A) Confocal images of live MDA-MB-231- β 1-GFP cells stained just prior to imaging with FM4-64 (120 nM). Panels include images of whole cells, the plasma membrane (PM) and the cytoplasm. Line profile shown on plasma membrane image demonstrates GFP/FM4-64 fluorescence. White arrowheads denote areas of β 1-GFP/FM4-64 overlap. (B) A 5 μm line profile across the plasma membrane of live MDA-MB-231- β 1-GFP cells. Data are mean (solid line) $\pm$ SEM (dotted line), $n = 10$ cells. (C) Quantification of FRET between GFP and FM4-64 within intracellular vesicles and at the plasma membrane. Regions of interest were photobleached using 100 iterations of a 561 nm laser (100 % laser power) to achieve 80-90 % bleaching of

FM4-64. GFP fluorescence (normalised to fluorescence of the first frame) between the pre-bleach and post-bleach recording were compared using an unpaired t-test. $n = 5-6$. Data are mean $\pm$ SEM. (D,E) MDA-MB-231- β 1-GFP cells were fixed and permeabilised with Triton X-100 (0.3 %) or digitonin (50 μ g/ml). Cells were labelled with antibodies for Lamin B2 (magenta) or GFP (green). (F) Quantification of the nuclear:cytoplasmic (N:C) signal density ratio between Triton X-100 and digitonin-permeabilised cells. Data are mean $\pm$ SEM ($n = 27 - 28$, $N = 3$). (G) Comparison of the cytoplasmic fluorescence intensity and nuclear fluorescence intensity between MDA-MB-231- β 1-GFP cells permeabilised with Triton X-100 or digitonin. Data are mean $\pm$ SEM ($n = 27 - 28$, $N = 3$). ns = not significant, * = $P < 0.05$, *** = $P < 0.001$, unpaired t test.

Figure 3. Subcellular distribution of β 1-GFP. MDA-MB-231- β 1-GFP cells were stained for (A) EEA1, (B) LAMP1, (C) GM130, (D) TGN46, (E) calnexin (all magenta), and DNA (DAPI, blue). Endogenous GFP is shown in green. Confocal microscopy with Airyscan technology was used for acquisition. (F) Quantification of the co-localisation of GFP and the indicated markers was calculated using Pearson's correlation coefficient. Data are mean $\pm$ SEM ($n = 25 - 29$, $N = 3$). * = $P < 0.05$; one-way ANOVA with Tukey's test. (G) MDA-MB-231- β 1-GFP cells were pre-treated with/without chloroquine (10 μ M, 24h), then fixed and endogenous GFP detected using confocal microscopy with Airyscan technology. White arrowheads indicate enlarged lysosomes.

Figure 4. Effect of γ -secretase inhibition on β 1-GFP function. (A) Schematic depicting sequential secretase processing of β 1-GFP. FL: full length, CTF: C-terminal fragment, ICD: intracellular domain. Ig: immunoglobulin loop. γ -secretase is inhibited by DAPT. (B) Western blot of lysates from MDA-MB-231- β 1-GFP cells treated with DMSO (0.01 % (v/v), 24 h) or DAPT (1 μ M, 24 h). Membranes were probed for GFP or α -tubulin. Quantification of

CTF:ICD band intensity is shown underneath. Data are mean $\pm$ SEM ($n = 4 - 5$, $N = 3$ extractions; unpaired t-test). (C) Representative Na^+ currents in MDA-MB-231- β 1-GFP cells pre-treated with DMSO (0.01 % (v/v), 24 h) or DAPT (1 μM , 24 h), following depolarisation between -80 mV and +30 mV for 250 ms from -120 mV. Peak current density (PCD) is compared on the right (unpaired t-test). Data are mean $\pm$ SEM ($n = 8$, $N = 3$). (D) Western blot of lysates from MDA-MB-231- β 1-GFP cells treated with DMSO (0.1% (v/v), 24 h), L685,458 (10 μM , 24 h) or Avagacestat (10 μM , 24 h). Membranes were probed for GFP or α -tubulin. Quantification of CTF/ICD band intensity is shown underneath ($n = 2$, $N = 2$). (E) Representative Na^+ currents in MDA-MB-231- β 1-GFP cells pre-treated with DMSO (0.1 % (v/v), 24 h) or Avagacestat (10 μM , 24 h). PCD is shown underneath. Data are mean $\pm$ SEM ($n = 7 - 8$, $N = 3$, unpaired t-test). (F) PCD in MDA-MB-231-GFP cells and MDA-MB-231- β 1-GFP cells following pre-treatment with DMSO ($n = 18$, $N = 3$), 1 μM L-685,458 ($n = 12$, $N = 3$) and 10 μM L-685,458 ($n = 7$, $N = 3$), one-way ANOVA. (G) Time taken for half-maximal recovery from inactivation for MDA-MB-231- β 1-GFP cells pre-treated with DMSO (0.01 – 0.1 % (v/v), 24 h), DAPT (1 μM , 24 h), Avagacestat (Ava, 10 μM , 24 h) or L,685-458 (1 μM , 24 h; $n = 8$, $N = 3$). Cells were depolarised to 0 mV for 25 ms, then held at -120 mV for t s before second depolarisation to 0 mV. t ranged from 1-500 ms. Data are mean $\pm$ SEM (unpaired t-test). ns = not significant, * = $P < 0.05$, ** = $P < 0.01$.

Figure 5. Effect of γ -secretase inhibition on β 1-GFP localisation. MDA-MB-231- β 1GFP cells were treated with DMSO (0.01 % (v/v), 24 h) or DAPT (1 μM , 24 h) and stained for EEA1 (A, magenta) or LAMP1 (B, magenta) and DNA (DAPI, blue). Endogenous GFP is shown in green. (C) Pearson's correlation coefficient (PCC) for co-localisation of GFP and EEA1 or LAMP1. Data are mean $\pm$ SEM ($n = 23 - 27$, $N = 3$), Mann Whitney U-test, ns = not significant, * = $P < 0.05$, ** = $P < 0.01$. (D) Representative recovery of GFP fluorescence at the leading edge of a live MDA-MB-231- β 1-GFP cell following photobleaching with a 488 nm laser (40 iterations, 100 % laser power). (E) Quantification of the recovery of GFP

fluorescence in MDA-MB-231- β 1-GFP cells at the leading and trailing edges following treatment with DMSO (0.01 % (v/v), 24 h, black line) or DAPT (1 μ M, 24 h, grey line). Data are mean (solid line) $\pm$ SEM (dotted line), $n = 25 - 28$, $N = 3$.

Figure 6. Function and subcellular localisation of β 1ICD-GFP. (A) Schematic of full-length β 1-GFP alongside β 1ICD-GFP. (B) Representative whole-cell Na^+ currents in MDA-MB-231-GFP, MDA-MB-231- β 1-GFP and MDA-MB-231- β 1ICD-GFP cells, following depolarisation between -80 mV and +30 mV, for 250 ms, from -120 mV. Peak current density (PCD) is shown on right. Data are mean $\pm$ SEM ($n = 14 - 16$, $N = 3$), Kruskal-Wallis test. (C) Recovery from inactivation and time taken for half-maximal recovery from inactivation ($t_{1/2}$) Cells were depolarised to 0 mV for 25 ms, then held at -120 mV for t s before re-stimulation at 0 mV. t ranged from 1-500 ms. Data are mean $\pm$ SEM ($n = 8$, $N = 3$). (D) Brightfield images of MDA-MB-231-GFP, MDA-MB-231- β 1-GFP and MDA-MB-231- β 1ICD-GFP cells at 20x magnification. Bottom row displays zoomed images from boxes above, with masks over example cells depicting circularity index ("C") and cell length. (E) Quantification of circularity index and cell length from brightfield images like those in D. Data are mean $\pm$ SEM ($n = 150$, $N = 3$), Kruskal-Wallis test. (F) Nuclear images of the GFP signal within fixed MDA-MB-231 cells expressing GFP, β 1-GFP or β 1ICD-GFP. Main panels show GFP signal (green), sub-panels depict DAPI (blue) and DAPI/GFP merge. (G) Nuclear:cytoplasmic signal density ratio (N:C ratio). Data are mean $\pm$ SEM ($n = 14 - 17$, $N = 3$), one-way ANOVA. ns = not significant, * = $P < 0.05$, ** = $P < 0.01$, **** = $P < 0.0001$.

Figure 7. Intracellular mobility of β 1ICD-GFP. (A) Live-cell confocal imaging of MDA-MB-231-GFP (top row) and MDA-MB-231- β 1ICD-GFP (bottom row) cells in the cytoplasm. Cells were imaged every 14 ms for 2 s and a 1.5 - 2 μ m wide region-of-interest photobleached with a 488 nm laser (100 % laser power, 40 iterations). Images displayed are immediately

prior to photobleaching (first column), immediately following photobleaching (second column) and 200 ms after photobleaching (third column). (B) Fluorescence recovery within the region of interest in the cytoplasm ($n = 15$, $N = 3$). Data are mean (solid line) $\pm$ SEM (dotted line). (C) Quantification of the mobile fraction in the cytoplasm ($n = 15$, $N = 3$). (D) Time taken for half-maximal fluorescence recovery (half-time, s) in the cytoplasm ($n = 15$, $N = 3$). (E) Live-cell confocal imaging of MDA-MB-231-GFP (top row) and MDA-MB-231- β 1ICD-GFP (bottom row) cells in the nucleus. Cells were imaged every 250 ms and photobleached with a 488 nm laser (100 % laser power, 40 iterations). Time series were acquired until five successive images without an increase in nuclear fluorescence were acquired. Images displayed are immediately prior to photobleaching (first column), immediately following photobleaching (second column) and 100 s after photobleaching (third column). Nuclei were photobleached following masking using the Hoechst 33342 signal (shown in sub-panels in the first column, blue). (F) Fluorescence recovery within the region of interest in the nucleus ($n = 10$, $N = 3$). Data are mean (solid line) $\pm$ SEM (dotted line). (G) Quantification of the mobile fraction in the nucleus ($n = 10$, $N = 3$). (H) Time taken for half-maximal fluorescence recovery (half-time, s) in the nucleus ($n = 10$, $N = 3$). Data are mean $\pm$ SEM. Unpaired t-tests were used to test significance, except Mann-Whitney U-test for H. ns = not significant, *** = $P < 0.001$.

Figure 8. Regulation of TTX-sensitive Na^+ current by β 1-GFP and β 1ICD-GFP. (A) Schematic of full-length β 1-GFP alongside β 1STOP-GFP. (B) Representative whole-cell Na^+ currents generated following depolarisation between -80 mV and +30 mV, for 250 ms, from -120 mV. Peak current density (PCD) is shown on right. Data are mean $\pm$ SEM ($n = 15$, $N = 3$), Kruskal-Wallis test. (C) Representative traces of I_{Na} in MDA-MB-231 cells expressing GFP, β 1-GFP, or β 1ICD-GFP in standard recording solution (PSS, black line), 1 μM TTX (orange line) and following washout (grey line). Quantification of the reduction in peak current density in 1 μM TTX and following washout is shown underneath, normalised to PSS.

Data are mean $\pm$ SEM (n = 6 - 9, N = 3), repeated measures ANOVA. ns = not significant, * = P<0.05, ***=P<0.001, **** = P < 0.0001.

Figure 9. Model for $\beta 1$ cycling in MDA-MB-231 cells. 1. $\beta 1$ progresses through the endoplasmic reticulum and Golgi apparatus. The majority of cellular $\beta 1$ is sequestered within the ER. 2. A fraction of $\beta 1$ is trafficked to the cell surface associated by its ICD to an α -subunit. 3. $\beta 1$ is either internalised (3a) or processed by secretases at the plasma membrane (3b). 4. Cleaved $\beta 1$ -ICD may be degraded or translocate to the nucleus to regulate gene expression.

bioRxiv preprint doi: <https://doi.org/10.1101/2021.12.29.474414>; this version posted December 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

A **B** **C**